REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
Elevar Therapeutics
Arvinas Inc.
DualityBio Inc.
Bold Therapeutics, Inc.
Genfit
Apollo Therapeutics Ltd
Alentis Therapeutics AG
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Alaunos Therapeutics
TriSalus Life Sciences, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Cogent Biosciences, Inc.
Medivir
TransThera Sciences (Nanjing), Inc.
BioNTech SE
NGM Biopharmaceuticals, Inc
TransThera Sciences (Nanjing), Inc.
NextCure, Inc.
Novo Nordisk A/S
Klus Pharma Inc.
Basilea Pharmaceutica
Beijing InnoCare Pharma Tech Co., Ltd.
Genoscience Pharma
SMT bio Co., Ltd.
Senhwa Biosciences, Inc.
Celgene
Immunitor LLC
FeRx